Top

Clinical Reviews in Allergy & Immunology

Published in:

01-10-2013

Immunoglobulin-Mediated Neuro-Cognitive Impairment: New Data and a Comprehensive Review

Authors: Assaf Menachem, Joab Chapman, Yael Deri, Chaim G. Pick, Aviva Katzav

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2013

Abstract

Excessive influx of immunoglobulin (IgG) into the brain has been reported to induce central nervous system (CNS) dysfunction. Depressed patients may exhibit immune activation manifested by elevated inflammatory markers and pro-inflammatory cytokines. The brain and especially the limbic system contain high concentrations of high affinity Fc receptors. We reviewed the literature on this phenomena and present data on the behavioral effects of pooled normal IgG on the brain. Many disease states are associated with depression and we examined whether this may be linked to high IgG influx. Female Balb/C mice were injected intra-cerbroventricularly with human immunoglobulin whole molecule, or human IgG F(ab′)₂ or Fc fragments. Control mice were injected with saline. The four groups were subjected to behavioral (staircase, forced swimming test, and elevated plus maze) and cognitive tests (passive avoidance test). IgG-injected mice exhibited depression-like behavior as reflected by significantly higher immobility time in the forced swimming test (p < 0.05) and hyperactive behavior as reflected by higher number of stairs climbed in the staircase test compared to controls (p < 0.01). Fc-fragments-injected mice showed hyperactive behavior as reflected by both higher number of stairs climbed and rearing events in the staircase test compared to controls. The results indicate that high levels of normal IgG in the cerebrospinal fluid can cause hyperactivity and depression-like behavior. The mechanism involved in these CNS manifestations include possibly Fc receptor binding.

Bien CG, Vincent A, Barnett MH et al (2012) Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135:1622–1638PubMedCrossRef

Kaida K, Kusunoki S (2010) Antibodies to gangliosides and ganglioside complexes in Guillain-Barre syndrome and Fisher syndrome: mini-review. J Neuroimmunol 223:5–12PubMedCrossRef

Zandman-Goddard G, Chapman J, Shoenfeld Y (2007) Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 36:297–315PubMedCrossRef

Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P (2001) Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 96:730–734PubMedCrossRef

Luborsky JL, Barua A, Shatavi SV, Kebede T, Abramowicz J, Rotmensch J (2005) Anti-tumor antibodies in ovarian cancer. Am J Reprod Immunol 54:55–62PubMedCrossRef

Zhong L, Peng X, Hidalgo GE, Doherty DE, Stromberg AJ, Hirschowitz EA (2004) Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics 4:1216–1225PubMedCrossRef

Melendez AJ, Bruetschy L, Floto RA, Harnett MM, Allen JM (2001) Functional coupling of FcgammaRI to nicotinamide adenine dinucleotide phosphate (reduced form) oxidative burst and immune complex trafficking requires the activation of phospholipase D1. Blood 98:3421–3428PubMedCrossRef

Stangel M, Compston A (2001) Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors. J Neuroimmunol 112:63–71PubMedCrossRef

Sanchez-Mejorada G, Rosales C (1998) Signal transduction by immunoglobulin Fc receptors. J Leukoc Biol 63:521–533PubMed

10.

Ravetch JV, Kinet JP (1991) Fc receptors. Annu Rev Immunol 9:457–492PubMedCrossRef

11.

van de Winkel JG, Capel PJ (1993) Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 14:215–221PubMedCrossRef

12.

Nakamura K, Hirai H, Torashima T et al (2007) CD3 and immunoglobulin G Fc receptor regulate cerebellar functions. Mol Cell Biol 27:5128–5134PubMedCrossRef

13.

Suemitsu S, Watanabe M, Yokobayashi E et al (2010) Fcgamma receptors contribute to pyramidal cell death in the mouse hippocampus following local kainic acid injection. Neuroscience 166:819–831PubMedCrossRef

14.

Namer IJ, Steibel J, Poulet P, Mauss Y, Mohr M, Chambron J (1994) The role of Mycobacterium tuberculosis in experimental allergic encephalomyelitis. Eur Neurol 34:224–227PubMedCrossRef

15.

Walls AF, Suckling AJ, Rumsby MG (1988) Autoantibody responses in the cerebrospinal fluid of guinea pigs with chronic relapsing experimental allergic encephalomyelitis. Acta Neurol Scand 78:422–428PubMedCrossRef

16.

Kamm C, Zettl UK (2012) Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev 11:196–202PubMedCrossRef

17.

Chavarria A, Alcocer-Varela J (2004) Is damage in central nervous system due to inflammation? Autoimmun Rev 3:251–260PubMedCrossRef

18.

Rabchevsky AG, Degos JD, Dreyfus PA (1999) Peripheral injections of Freund’s adjuvant in mice provoke leakage of serum proteins through the blood–brain barrier without inducing reactive gliosis. Brain Res 832:84–96PubMedCrossRef

19.

Shrot S, Katzav A, Korczyn AD et al (2002) Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 11:736–743PubMedCrossRef

20.

Holmes GP, Kaplan JE, Gantz NM et al (1988) Chronic fatigue syndrome: a working case definition. Ann Intern Med 108:387–389PubMedCrossRef

21.

Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G (2009) Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 8:287–291PubMedCrossRef

22.

Hokama Y, Empey-Campora C, Hara C et al (2008) Acute phase phospholipids related to the cardiolipin of mitochondria in the sera of patients with chronic fatigue syndrome (CFS), chronic Ciguatera fish poisoning (CCFP), and other diseases attributed to chemicals, Gulf War, and marine toxins. J Clin Lab Anal 22:99–105PubMedCrossRef

23.

Konstantinov K, von Mikecz A, Buchwald D, Jones J, Gerace L, Tan EM (1996) Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J Clin Invest 98:1888–1896PubMedCrossRef

24.

Wheatland R (2005) Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic–pituitary–adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression. Med Hypotheses 65:287–295PubMedCrossRef

25.

Vernon SD, Reeves WC (2005) Evaluation of autoantibodies to common and neuronal cell antigens in Chronic Fatigue Syndrome. J Autoimmune Dis 2:5PubMedCrossRef

26.

Klein R, Berg PA (1995) High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. Eur J Med Res 1:21–26PubMed

27.

Heller U, Becker EW, Zenner HP, Berg PA (1998) Incidence and clinical relevance of antibodies to phospholipids, serotonin and ganglioside in patients with sudden deafness and progressive inner ear hearing loss. HNO 46:583–586PubMedCrossRef

28.

Feinstein A (2011) Multiple sclerosis and depression. Mult Scler 17:1276–1281PubMedCrossRef

29.

Luque FA, Jaffe SL (2007) Cerebrospinal fluid analysis in multiple sclerosis. Int Rev Neurobiol 79:341–356PubMedCrossRef

30.

Chapman J, Abu-Katash M, Inzelberg R et al (2002) Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci 203–204:81–84PubMedCrossRef

31.

Bluestein HG, Williams GW, Steinberg AD (1981) Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 70:240–246PubMedCrossRef

32.

Danon YL, Garty BZ (1986) Autoantibodies to neuroblastoma cell surface antigens in neuropsychiatric lupus. Neuropediatrics 17:23–27PubMedCrossRef

33.

Katzav A, Shoenfeld Y, Chapman J (2010) The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clin Rev Allergy Immunol 38:196–200PubMedCrossRef

34.

Liberato B, Levy RA (2007) Antiphospholipid syndrome and cognition. Clin Rev Allergy Immunol 32:188–191PubMedCrossRef

35.

Katzav A, Pick CG, Korczyn AD et al (2001) Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 10:496–499PubMedCrossRef

36.

Omdal R, Brokstad K, Waterloo K, Koldingsnes W, Jonsson R, Mellgren SI (2005) Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 12:392–398PubMedCrossRef

37.

Peery HE, Day GS, Dunn S, et al (2012) Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev 11:863–872

38.

D’Andrea MR (2005) Add Alzheimer’s disease to the list of autoimmune diseases. Med Hypotheses 64:458–463PubMedCrossRef

39.

Sardi F, Fassina L, Venturini L et al (2011) Alzheimer’s disease, autoimmunity and inflammation. The good, the bad and the ugly. Autoimmun Rev 11:149–153PubMedCrossRef

40.

D’Andrea MR (2005) Evidence that immunoglobulin-positive neurons in Alzheimer’s disease are dying via the classical antibody-dependent complement pathway. Am J Alzheimers Dis Other Demen 20:144–150PubMedCrossRef

41.

Ryu JK, McLarnon JG (2009) A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain. J Cell Mol Med 13:2911–2925PubMedCrossRef

42.

Colasanti T, Barbati C, Rosano G, Malorni W, Ortona E (2010) Autoantibodies in patients with Alzheimer’s disease: pathogenetic role and potential use as biomarkers of disease progression. Autoimmun Rev 9:807–811PubMedCrossRef

43.

Chapman J, Alroy G, Weiss Z, Faigon M, Feldon J, Michaelson DM (1991) Anti-neuronal antibodies similar to those found in Alzheimer’s disease induce memory dysfunction in rats. Neuroscience 40:297–305PubMedCrossRef

44.

Chapman J, Feldon J, Alroy G, Michaelson DM (1989) Immunization of rats with cholinergic neurons induces behavioral deficits. J Neural Transplant 1:63–76PubMedCrossRef

45.

Benkler M, Agmon-Levin N, Hassin-Baer S et al (2012) Immunology, autoimmunity, and autoantibodies in Parkinson’s disease. Clin Rev Allergy Immunol 42:164–171PubMedCrossRef

46.

Belmaker RH, Agam G (2008) Major depressive disorder. N Engl J Med 358:55–68PubMedCrossRef

47.

Hasin DS, Goodwin RD, Stinson FS, Grant BF (2005) Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 62:1097–1106PubMedCrossRef

48.

Dowlati Y, Herrmann N, Swardfager W et al (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457PubMedCrossRef

49.

Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Cales P, Garre JB (2003) Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 4:115–118PubMedCrossRef

50.

Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71:171–186PubMedCrossRef

51.

Kronfol Z (2002) Immune dysregulation in major depression: a critical review of existing evidence. Int J Neuropsychopharmacol 5:333–343PubMedCrossRef

52.

Kronfol Z, House JD (1989) Lymphocyte mitogenesis, immunoglobulin and complement levels in depressed patients and normal controls. Acta Psychiatr Scand 80:142–147PubMedCrossRef

53.

Maes M (1995) Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19:11–38PubMedCrossRef

54.

Maes M, Scharpe S, Meltzer HY et al (1993) Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic–pituitary–adrenal axis in severe depression. Psychiatry Res 49:11–27PubMedCrossRef

55.

Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P (1998) Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25:39–47PubMed

56.

Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56PubMedCrossRef

57.

Kent S, Bluthe RM, Kelley KW, Dantzer R (1992) Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13:24–28PubMedCrossRef

58.

Fantuzzi G, Dinarello CA (1996) The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice. J Leukoc Biol 59:489–493PubMed

59.

Krueger JM, Majde JA, Obal F (2003) Sleep in host defense. Brain Behav Immun 17(Suppl 1):S41–S47PubMedCrossRef

60.

Swiergiel AH, Smagin GN, Johnson LJ, Dunn AJ (1997) The role of cytokines in the behavioral responses to endotoxin and influenza virus infection in mice: effects of acute and chronic administration of the interleukin-1-receptor antagonist (IL-1ra). Brain Res 776:96–104PubMedCrossRef

61.

Adler G, Gattaz WF (1993) Pain perception threshold in major depression. Biol Psychiatry 34:687–689PubMedCrossRef

62.

Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF (1994) Characterization of cytokine-induced hyperalgesia. Brain Res 654:15–26PubMedCrossRef

63.

Song X, Shapiro S, Goldman DL, Casadevall A, Scharff M, Lee SC (2002) Fcgamma receptor I- and III-mediated macrophage inflammatory protein 1alpha induction in primary human and murine microglia. Infect Immun 70:5177–5184PubMedCrossRef

64.

Song X, Tanaka S, Cox D, Lee SC (2004) Fcgamma receptor signaling in primary human microglia: differential roles of PI-3K and Ras/ERK MAPK pathways in phagocytosis and chemokine induction. J Leukoc Biol 75:1147–1155PubMedCrossRef

65.

Lunnon K, Teeling JL, Tutt AL, Cragg MS, Glennie MJ, Perry VH (2011) Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J Immunol 186:7215–7224PubMedCrossRef

66.

Hastings RS, Parsey RV, Oquendo MA, Arango V, Mann JJ (2004) Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. Neuropsychopharmacol 29:952–959CrossRef

67.

Mayberg HS, Lozano AM, Voon V et al (2005) Deep brain stimulation for treatment-resistant depression. Neuron 45:651–660PubMedCrossRef

68.

Heo Y, Zhang Y, Gao D, Miller VM, Lawrence DA (2011) Aberrant immune responses in a mouse with behavioral disorders. PLoS One 6:e20912PubMedCrossRef

69.

Katzav A, Solodeev I, Brodsky O et al (2007) Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum 56:938–948PubMedCrossRef

70.

Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y (2010) Evidence for the use of intravenous immunoglobulins—a review of the literature. Clin Rev Allergy Immunol 38:201–269PubMedCrossRef

71.

Sapir T, Shoenfeld Y (2005) Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol 29:185–199PubMedCrossRef

72.

Kaveri SV (2012) Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 11:792–794PubMedCrossRef

Title: Immunoglobulin-Mediated Neuro-Cognitive Impairment: New Data and a Comprehensive Review
Authors: Assaf Menachem
Joab Chapman
Yael Deri
Chaim G. Pick
Aviva Katzav
Publication date: 01-10-2013
Publisher: Springer US
Published in: Clinical Reviews in Allergy & Immunology / Issue 2/2013
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-013-8357-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Immunoglobulin-Mediated Neuro-Cognitive Impairment: New Data and a Comprehensive Review

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Vitamin D in Systemic and Organ-Specific Autoimmune Diseases

Regaining Tolerance to a Self-antigen by the Modified Vaccination Technique

The Implication of Vitamin D and Autoimmunity: a Comprehensive Review

Autoimmunity in 2012

Genetics of Rheumatoid Arthritis — A Comprehensive Review

Tolerance and Autoimmunity in Primary Immunodeficiency Disease: a Comprehensive Review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page